文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌新辅助化疗中期再分期纵向研究

A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
PubMed 文献 · BJU Int · 2021-09-19

结果显示两个周期后再分期仅改变1.1%患者的管理,完成NAC后再分期是总生存的强预测因子。

要点

  • 两个周期NAC后再分期很少改变患者管理,可考虑省略。
  • 完成NAC后CT再分期是总生存的强预测因子。
  • 完成NAC后临床降期者死亡风险更低(HR 0.49)。

核心结论

  • 两个周期NAC后再分期提供的信息有限,很少改变患者管理,或可省略。
  • 完成NAC后CT再分期是总生存的强预测因子。

研究设计与样本

  • 共180例患者,其中110例接受至少四个周期NAC且有完整影像资料。

主要发现

  • 整个队列中,两个周期NAC后仅2/180例(1.1%)因影像学发现改变后续管理。
  • 两个周期后稳定但至少四个周期NAC后降期的患者死亡风险 similarly 降低(HR 0.53)。
  • 仅1例两个周期后降期的患者在四个周期后升期。
  • 51例(46%)观察到临床降期,55例(50%)临床分期无变化,4例(3.6%)临床升期。
  • 完成NAC后临床降期者较无变化或升期者死亡风险更低(HR 0.49,95%CI 0.25-0.94;P=0.033)。

临床怎么用

  • 对于肌层浸润性膀胱癌,可考虑省略两个周期NAC后的影像学再分期。
  • 完成NAC后应进行CT再分期以评估预后。

局限性

  • 单中心研究,样本量有限。
  • 仅110例接受至少四个周期NAC且有完整影像资料。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the usefulness of radiological re-staging after two and four cycles of neoadjuvant chemotherapy (NAC), the impact of re-staging on further patient management, and the correlation between clinical and final pathological tumour stage at radical cystectomy (RC). PATIENTS AND METHODS: We conducted a longitudinal, single-centre, cohort study of prospectively collected consecutive patients who underwent NAC and RC for urothelial muscle-invasive bladder cancer between July 2001 and December 2017. Patients underwent repeated computed tomography scans for re-staging after two cycles of NAC and after completion of NAC before RC. RESULTS: Of 180 patients, 110 had ≥four cycles of NAC and had complete imaging available. In the entire cohort, further patient management was only changed in 2/180 patients (1.1%) after two cycles of NAC based on radiological findings. Patients who were stable after two cycles but then downstaged after at least four cycles of NAC had a similarly lowered risk of death (hazard ratio [HR] 0.53). Only one patient downstaged after two cycles was subsequently upstaged after four cycles. Clinical downstaging was observed in 51 patients (46%), 55 patients (50%) had no change in clinical stage and four patients (3.6%) were clinically upstaged. Patients clinically downstaged after four cycles of NAC had a lower risk of death (HR 0.49, 95% confidence interval 0.25-0.94; P = 0.033) compared to those with no change or upstaged after completion of NAC. CONCLUSIONS: Re-staging of muscle-invasive bladder cancer after two cycles of NAC offers little additional information, rarely changes patient management, and may therefore be omitted, whereas re-staging after completion of NAC by CT is a strong predictor of overall survival.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Furrer MA, Papa N, Luetolf S, et al. A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer. BJU Int. 2021. PMID: 34418255. doi:10.1111/bju.15579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。